Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golcadomide + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma
NCT07578077Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Dec 2026
- Primary completion
- Apr 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of golcadomide in mantle cell lymphoma (MCL), sponsored by City of Hope. Planned start Dec 2026; status: recruiting.
02
Drugs
golcadomide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07578077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07578077.